Developer docs
API playgroundTry for free, no card

Search company profiles

Tyche

Full company profile

uuid003e5ek

Namestring
Tyche
Legal namestring
Tyche Industries Limited
Company typeenum
Public
Founded yearint
1998
Descriptiontext

Tyche Industries Limited is a publicly listed (BSE: 532384) pharmaceutical manufacturer founded in 1998 and headquartered in Hyderabad, India. The company manufactures Active Pharmaceutical Ingredients (APIs), Advanced and Chiral Intermediates, Glucosamine-based Nutraceuticals, and offers full-service Contract Development and Manufacturing Organization (CDMO) capabilities to global pharmaceutical clients. Its commercial portfolio spans 19 APIs across therapeutic categories including CNS (Sertraline, Fluoxetine, Donepezil), anti-emetic (Palonosetron), anti-retroviral (Tenofovir variants), anti-histamine (Cetirizine, Rupatadine), urology (Silodosin, Solifenacin, Tamsulosin), anti-microbial (Nitrofurantoin), and anti-arthritic (Glucosamine), with five additional APIs in development.

Manufacturing is concentrated at a single Kakinada, Andhra Pradesh facility comprising 7 production blocks across 28,844 square meters with 210,000 liters of reactor volume and 6 clean rooms. Reactor capacity spans 100L to 6,300L with operating temperatures from -30°C to 270°C, supporting a wide reaction portfolio including asymmetric synthesis, hydrogenation, Grignard, nitration, and chiral resolution. The company holds USFDA, PMDA (Japan), WHO GMP, and CDSCO certifications, and in September 2025 successfully cleared Brazil's ANVISA GMP inspection. R&D is conducted by PhD- and Masters-level chemists at a kilo- and pilot-plant-equipped center covering route development, IP evaluation, impurity characterization, and polymorphic studies.

Tyche generates revenue through direct B2B enterprise sales of catalog APIs to pharmaceutical companies, supported by multi-jurisdictional Drug Master File (USDMF, EUDMF, KDMF, JDMF, Canadian DMF) submissions and CEP-granted status, plus project-based CDMO revenue from custom synthesis, process development, and contract manufacturing with tech-transfer from client sites. Pricing is quote-based and negotiated per contract rather than transactionally listed. The company is led by Managing Director and Chairman G Sandeep and Executive Director G Ganesh Kumar, with a founder-family ownership structure evident from G-prefixed executive names and no disclosed private equity or venture capital sponsorship.

Short descriptiontext

Tyche Industries Limited is an Indian B2B manufacturer of Active Pharmaceutical Ingredients, Chiral Intermediates, Nutraceuticals, and CDMO services, selling to global pharmaceutical companies from a single Kakinada manufacturing facility under USFDA, PMDA, WHO, CDSCO, and ANVISA GMP certifications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersHyderabad, India
HQ citystring
Hyderabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
active pharmaceutical ingredients, pharmaceutical intermediates, contract manufacturing, nutraceutical ingredients, chiral chemistry
Industry1 code
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Pharmaceutical Preparations2834
Product category
Active Pharmaceutical Ingredients Manufacturing
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Active Pharmaceutical Ingredients (API) Sales
TypeOne Time License
Description

Manufacturing and sale of commercial APIs including Sertraline HCI, Fluoxetine, Racecadotril, Palonosetron HCI, Silodosin, Solifenacin Succinate, Tamsulosin HCI, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide Fumarate, Rupatadine Fumarate, Glucosamine variants, Nitrofurantoin variants, Donepezil HCI, and Cetirizine HCI to pharmaceutical companies.

tycheindustries.net
2CDMO Services
TypeProfessional Services
Description

Contract Development and Manufacturing Organization services including Chemical Process Development, Drug Substance manufacture and Custom Synthesis, CMC & Regulatory Support, Analytical Development Services (Method Development, Validation, Impurity identification, Characterization, Reference standard characterization, Stability Studies), and Contract Manufacture of APIs & Starting Materials with tech-transfer from client sites.

tycheindustries.net
3Advanced and Chiral Intermediates
TypeOne Time License
Description

Manufacturing and supply of pharmaceutical intermediates used in API synthesis, including Sertraline intermediates, Tamsulosin intermediates, Raloxifene/Flavoxate intermediates, Solifenacin intermediates, Tenofovir intermediates, and Donepezil intermediates.

tycheindustries.net
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Tyche Industries manufactures Active Pharmaceutical Ingredients (APIs), Advanced & Chiral Intermediates, and Glucosamine-based Nutraceuticals at its Kakinada facility, and provides CDMO services including chemical process development, custom synthesis, analytical development, CMC & regulatory support, and contract manufacturing of APIs and starting materials. The company serves global pharmaceutical companies across CNS, anti-emetic, anti-retroviral, anti-histamine, anti-arthritic, urological, anti-microbial, and anti-diarrheal therapeutic categories.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Successfully completed ANVISA GMP inspection at Kakinada facility in September 2025
Product overview1 text field

Tyche Industries is a manufacturer of Active Pharmaceutical Ingredients (APIs), Advanced Intermediates, and Chiral Intermediates, headquartered in Hyderabad, India. The company's product portfolio consists of four core offerings: (1) Commercial and development-stage APIs covering multiple therapeutic categories; (2) Advanced and Chiral Intermediates used as pharmaceutical building blocks; (3) Glucosamine-based Nutraceuticals for joint health; and (4) CDMO services providing contract development and manufacturing for APIs and fine chemicals. The company also offers regulatory filing services including DMF and CEP submissions for international markets.

Product and service2 records
1Active Pharmaceutical Ingredients (APIs)
CategoryActive Pharmaceutical Ingredients
Description

Commercial and development-stage Active Pharmaceutical Ingredients covering multiple therapeutic categories. Manufactured and supplied to global pharmaceutical companies for finished drug formulation, with regulatory filings (DMF, CEP) supporting client product approvals in US, EU, Japan, Korea, and other markets.

2Advanced & Chiral Intermediates
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Divi's Laboratories
TypeDirect peer
Description

India-headquartered API and intermediates manufacturer with strong CDMO operations, USFDA/EMA-approved facilities, and a global generic-API franchise. Closest direct peer to Tyche in scale, regulatory footprint, and contract services orientation.

2Laurus Labs
TypeDirect peer
Description

Indian API and CDMO company serving global generics and ARV markets, with comparable USFDA-inspected manufacturing and contract development capabilities. Highly comparable on customer base (anti-retrovirals, CNS) and CDMO growth thesis.

3Hikal
TypeDirect peer
Description

India-based manufacturer of APIs, intermediates, and fine chemicals with CDMO services and USFDA/EDQM certifications. Comparable on size, product mix (specialty small molecules), and B2B pharma customer base.

4Sai Life Sciences
TypeDirect peer
Description

Indian CDMO offering custom synthesis, process development, and API manufacturing for innovator and generic pharma. Comparable contract-services model and USFDA/EMA-grade quality systems.

5Granules India
TypeDirect peer
Description

Indian manufacturer of APIs, pharmaceutical intermediates, and finished dosages with global regulatory filings. Comparable customer base and product mix in commodity generics.

6Ipca Laboratories
TypeDirect peer
Description

Indian pharma company manufacturing APIs and formulations across therapeutic categories including anti-arthritic and anti-malarial, with USFDA-approved plants. Comparable API manufacturing capability and export focus.

7Aurobindo Pharma
TypeBroad incumbent
Description

Large Indian vertically-integrated pharma with substantial API manufacturing and global generics presence. Overlaps with Tyche on API capability but operates at much larger scale and across finished formulations.

8Natco Pharma
TypeDirect peer
Description

Indian pharma with API manufacturing for generics and niche molecules, including complex chemistries. Comparable customer profile in regulated-market generics.

9Dr. Reddy's Laboratories
TypeBroad incumbent
Description

Major Indian pharma with API and finished dosage operations serving global markets. Overlaps with Tyche on the API side but is significantly larger and more diversified.

10Sequent Scientific
TypeEmerging player
Description

India-based manufacturer of APIs and intermediates with regulatory certifications. Comparable manufacturing-services model though more focused on animal health adjacencies.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tyche

Active Pharmaceutical Ingredients Manufacturingtycheindustries.net

Tyche Industries Limited is an Indian B2B manufacturer of Active Pharmaceutical Ingredients, Chiral Intermediates, Nutraceuticals, and CDMO services, selling to global pharmaceutical companies from a single Kakinada manufacturing facility under USFDA, PMDA, WHO, CDSCO, and ANVISA GMP certifications.

What Tyche does

Tyche Industries Limited is a publicly listed (BSE: 532384) pharmaceutical manufacturer founded in 1998 and headquartered in Hyderabad, India. The company manufactures Active Pharmaceutical Ingredients (APIs), Advanced and Chiral Intermediates, Glucosamine-based Nutraceuticals, and offers full-service Contract Development and Manufacturing Organization (CDMO) capabilities to global pharmaceutical clients. Its commercial portfolio spans 19 APIs across therapeutic categories including CNS (Sertraline, Fluoxetine, Donepezil), anti-emetic (Palonosetron), anti-retroviral (Tenofovir variants), anti-histamine (Cetirizine, Rupatadine), urology (Silodosin, Solifenacin, Tamsulosin), anti-microbial (Nitrofurantoin), and anti-arthritic (Glucosamine), with five additional APIs in development.

Manufacturing is concentrated at a single Kakinada, Andhra Pradesh facility comprising 7 production blocks across 28,844 square meters with 210,000 liters of reactor volume and 6 clean rooms. Reactor capacity spans 100L to 6,300L with operating temperatures from -30°C to 270°C, supporting a wide reaction portfolio including asymmetric synthesis, hydrogenation, Grignard, nitration, and chiral resolution. The company holds USFDA, PMDA (Japan), WHO GMP, and CDSCO certifications, and in September 2025 successfully cleared Brazil's ANVISA GMP inspection. R&D is conducted by PhD- and Masters-level chemists at a kilo- and pilot-plant-equipped center covering route development, IP evaluation, impurity characterization, and polymorphic studies.

Tyche generates revenue through direct B2B enterprise sales of catalog APIs to pharmaceutical companies, supported by multi-jurisdictional Drug Master File (USDMF, EUDMF, KDMF, JDMF, Canadian DMF) submissions and CEP-granted status, plus project-based CDMO revenue from custom synthesis, process development, and contract manufacturing with tech-transfer from client sites. Pricing is quote-based and negotiated per contract rather than transactionally listed. The company is led by Managing Director and Chairman G Sandeep and Executive Director G Ganesh Kumar, with a founder-family ownership structure evident from G-prefixed executive names and no disclosed private equity or venture capital sponsorship.

Tyche firmographics

Firmographics
Name
Tyche
Legal name
Tyche Industries Limited
Website
https://tycheindustries.net
Company type
Public
Founded year
1998
Operating status
Operating
Headcount range
101–250 employees
Short description
Tyche Industries Limited is an Indian B2B manufacturer of Active Pharmaceutical Ingredients, Chiral Intermediates, Nutraceuticals, and CDMO services, selling to global pharmaceutical companies from a single Kakinada manufacturing facility under USFDA, PMDA, WHO, CDSCO, and ANVISA GMP certifications.
Ownership category
akta.pro rank

Tyche industry classification

Industry
Product category
Active Pharmaceutical Ingredients Manufacturing
NAICS
Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Active pharmaceutical ingredients
  • Pharmaceutical intermediates
  • Contract manufacturing
  • Nutraceutical ingredients
  • Chiral chemistry

Where Tyche is headquartered

Location

Headquarters

HQ city
Hyderabad
HQ country
India
HQ region
Asia

Offices2 records

Markets served

Tyche business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Active Pharmaceutical Ingredients (API) Sales: Manufacturing and sale of commercial APIs including Sertraline HCI, Fluoxetine, Racecadotril, Palonosetron HCI, Silodosin, Solifenacin Succinate, Tamsulosin HCI, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide Fumarate, Rupatadine Fumarate, Glucosamine variants, Nitrofurantoin variants, Donepezil HCI, and Cetirizine HCI to pharmaceutical companies.
  2. CDMO Services: Contract Development and Manufacturing Organization services including Chemical Process Development, Drug Substance manufacture and Custom Synthesis, CMC & Regulatory Support, Analytical Development Services (Method Development, Validation, Impurity identification, Characterization, Reference standard characterization, Stability Studies), and Contract Manufacture of APIs & Starting Materials with tech-transfer from client sites.
  3. Advanced and Chiral Intermediates: Manufacturing and supply of pharmaceutical intermediates used in API synthesis, including Sertraline intermediates, Tamsulosin intermediates, Raloxifene/Flavoxate intermediates, Solifenacin intermediates, Tenofovir intermediates, and Donepezil intermediates.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Tyche product offering

Product offering

Core offering

Tyche Industries manufactures Active Pharmaceutical Ingredients (APIs), Advanced & Chiral Intermediates, and Glucosamine-based Nutraceuticals at its Kakinada facility, and provides CDMO services including chemical process development, custom synthesis, analytical development, CMC & regulatory support, and contract manufacturing of APIs and starting materials. The company serves global pharmaceutical companies across CNS, anti-emetic, anti-retroviral, anti-histamine, anti-arthritic, urological, anti-microbial, and anti-diarrheal therapeutic categories.

Product overview

Tyche Industries is a manufacturer of Active Pharmaceutical Ingredients (APIs), Advanced Intermediates, and Chiral Intermediates, headquartered in Hyderabad, India. The company's product portfolio consists of four core offerings: (1) Commercial and development-stage APIs covering multiple therapeutic categories; (2) Advanced and Chiral Intermediates used as pharmaceutical building blocks; (3) Glucosamine-based Nutraceuticals for joint health; and (4) CDMO services providing contract development and manufacturing for APIs and fine chemicals. The company also offers regulatory filing services including DMF and CEP submissions for international markets.

Differentiator

Problem solved

Functional benefit

Products and services

  • Active Pharmaceutical Ingredients (APIs) Commercial and development-stage Active Pharmaceutical Ingredients covering multiple therapeutic categories. Manufactured and supplied to global pharmaceutical companies for finished drug formulation, with regulatory filings (DMF, CEP) supporting client product approvals in US, EU, Japan, Korea, and other markets.
  • Advanced & Chiral Intermediates

Quantifiable outcome

  • Successfully completed ANVISA GMP inspection at Kakinada facility in September 2025

Companies that use Tyche

Customer profile

Segments2 records

Ideal customer profiles2 records

Tyche technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Tyche partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Tyche competitors and assessment

Company assessment

Direct peers

  • Divi's Laboratories: India-headquartered API and intermediates manufacturer with strong CDMO operations, USFDA/EMA-approved facilities, and a global generic-API franchise. Closest direct peer to Tyche in scale, regulatory footprint, and contract services orientation.
  • Laurus Labs: Indian API and CDMO company serving global generics and ARV markets, with comparable USFDA-inspected manufacturing and contract development capabilities. Highly comparable on customer base (anti-retrovirals, CNS) and CDMO growth thesis.
  • Hikal: India-based manufacturer of APIs, intermediates, and fine chemicals with CDMO services and USFDA/EDQM certifications. Comparable on size, product mix (specialty small molecules), and B2B pharma customer base.
  • Sai Life Sciences: Indian CDMO offering custom synthesis, process development, and API manufacturing for innovator and generic pharma. Comparable contract-services model and USFDA/EMA-grade quality systems.
  • Granules India: Indian manufacturer of APIs, pharmaceutical intermediates, and finished dosages with global regulatory filings. Comparable customer base and product mix in commodity generics.
  • Ipca Laboratories: Indian pharma company manufacturing APIs and formulations across therapeutic categories including anti-arthritic and anti-malarial, with USFDA-approved plants. Comparable API manufacturing capability and export focus.
  • Natco Pharma: Indian pharma with API manufacturing for generics and niche molecules, including complex chemistries. Comparable customer profile in regulated-market generics.

Broad incumbents

  • Aurobindo Pharma: Large Indian vertically-integrated pharma with substantial API manufacturing and global generics presence. Overlaps with Tyche on API capability but operates at much larger scale and across finished formulations.
  • Dr. Reddy's Laboratories: Major Indian pharma with API and finished dosage operations serving global markets. Overlaps with Tyche on the API side but is significantly larger and more diversified.

Emerging players

  • Sequent Scientific: India-based manufacturer of APIs and intermediates with regulatory certifications. Comparable manufacturing-services model though more focused on animal health adjacencies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Tyche compliance and trust

Trust signal

Compliance5 records

Tyche financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tyche leadership team

Management profile

Number of profiles

Profiles9 records

Tyche funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tyche M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tyche

What does Tyche do?

Tyche Industries manufactures Active Pharmaceutical Ingredients (APIs), Advanced & Chiral Intermediates, and Glucosamine-based Nutraceuticals at its Kakinada facility, and provides CDMO services including chemical process development, custom synthesis, analytical development, CMC & regulatory support, and contract manufacturing of APIs and starting materials. The company serves global pharmaceutical companies across CNS, anti-emetic, anti-retroviral, anti-histamine, anti-arthritic, urological, anti-microbial, and anti-diarrheal therapeutic categories.

Is Tyche a public or private company?

Tyche is a public company. It is classified as public and is currently operating.

When was Tyche founded?

Tyche was founded in 1998. It employs 101 to 250 people.

Where is Tyche based?

Tyche is headquartered in Hyderabad, India, in the Asia region.

How does Tyche make money?

Three revenue lines are on record. Active Pharmaceutical Ingredients (API) Sales are the primary driver. The others are CDMO Services and advanced and Chiral Intermediates.

Who are Tyche's main competitors?

Direct peers on record are Divi's Laboratories, Laurus Labs, Hikal, Sai Life Sciences, Granules India, Ipca Laboratories and Natco Pharma. Broad incumbents are Aurobindo Pharma and Dr. Reddy's Laboratories. Sequent Scientific is listed as an emerging player.

Does Tyche have an API?

No public API is recorded for Tyche.

What industry is Tyche in?

Tyche's product category is Active Pharmaceutical Ingredients Manufacturing. Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO. Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals